Canada’s two-tiered process of approving potentially life-saving oncology drugs is preventing cancer patients in some provinces from accessing medication that’s readily available in other parts of the country, according to a new study. The study, released by think-tank Fraser Institute, looks at the effectiveness of the pan-Canadian Oncology Drug Review (pCODR), which was established in 2010 to recommend new cancer drugs to all the provinces and territories, except Quebec. Read more here.
Read the report, Has pCODR improved access to oncology drugs?, here.
No comments:
Post a Comment